Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All losartan studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchLosartanLosartan (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Does Losartan reduce the severity of COVID-19 in hypertensive patients?

Mirjalili et al., BMC Cardiovascular Disorders, doi:10.1186/s12872-022-02548-2
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 81% Improvement Relative Risk Case 3% Losartan for COVID-19  Mirjalili et al.  Prophylaxis Is prophylaxis with losartan beneficial for COVID-19? Retrospective 280 patients in Iran Lower mortality with losartan (p=0.003) c19early.org Mirjalili et al., BMC Cardiovascular D.., Mar 2022 Favorslosartan Favorscontrol 0 0.5 1 1.5 2+
Retrospective study of 280 hypertensive patients in Iran showing lower mortality with losartan use in COVID-19 patients, however data is contradictory and unclear. The text and Figure 1 indicate that 179 of 280 patients were PCR+, however Table 1 shows 101 patients were PCR+. Table 1 shows 11% of PCR- patients died, authors do not provide an explanation for the very high mortality of PCR- patients. The followup period for the outcomes is not specified. The reported exclusions in Figure 1 does not match the description of the resulting 280 patients as hypertensive. Authors indicate that the patients "presented to COVID-19 laboratory and diagnostic centers", it is unclear why almost all were hospitalized, including the PCR- patients.
risk of death, 81.2% lower, RR 0.19, p = 0.003, treatment 161, control 119, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
risk of case, 3.3% lower, RR 0.97, p = 0.86, treatment 161, control 119, odds ratio converted to relative risk, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mirjalili et al., 19 Mar 2022, retrospective, Iran, peer-reviewed, mean age 64.6, 5 authors. Contact: adehghani42@yahoo.com (corresponding author).
This PaperLosartanAll
Does Losartan reduce the severity of COVID-19 in hypertensive patients?
Mohammadreza Mirjalili, Moslem Taheri Soodejani, Mehdi Raadabadi, Ali Dehghani, Fateme Salemi
BMC Cardiovascular Disorders, doi:10.1186/s12872-022-02548-2
Background: One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients. Methods: The research sample of analytical study included 1458 patients presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher's exact test, t test, and logistic regression. Results: Of 1458 subjects that were studied, 280 were hypertensive of whom 179 tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 times in hypertensive patients who used losartan (P = 0.003). Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive patients, it was found that this medicine played a protective role although this relationship was not statistically significant (P = 0.86). Conclusions: The results showed that losartan reduced the chance of mortality in hypertensive patients. It is recommended that the effect of losartan and other blood pressure medicines on COVID-19 patients be investigated in larger studies as well as laboratory investigations.
Authors' contributions MM and AD have designed the study and supervised the thesis. MR collected the data and analyzed it. They also prepared the first draft of the manuscript. MTS has edited and finalized the manuscript. All authors read the manuscript and approved it. Declarations Ethics approval and consent to participate The article's proposal was approved by the ethics committee of Shahid Sadoughi University of Medical Sciences with the ID of IR.SSU.REC.1399.101. Due to the retrospective nature of the study, no study specific consent form was used. However, patients admitted to our hospital are asked to sign a general consent upon admission, which covers the collection of patient data and publication of these results. Therefore, the individual's informed consent was waived by the above ethics committee. We received administrative permission from (Secretary of University/Regional Research Ethics Committee Shahid Sadoughi University of Medical Sciences) to access and use the data. Data used in the study were anonymized. The ethics committee approved this procedure with the above ethical code. The present study was conducted in terms of the principles of the revised Declaration of Helsinki, which waived requirement for informed consent. Consent for publication Not applicable. Competing interests All authors declare that they have no conflict of interest regarding this study. • fast, convenient online submission • thorough peer review by experienced researchers in..
References
Alshahrani, Sindi, Alshamsi, Al-Omari, El Tahan et al., Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus, Ann Intensive Care, doi:10.12659/msm.925364
Arabi, Alothman, Balkhy, Al-Dawood, Aljohani et al., Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial, Trials, doi:10.1186/s13063-017-2427-0
Choi, Kim, Ju, -H, Lee et al., The effects of losartan on cytomegalovirus infection in human trabecular meshwork cells, Plos one, doi:10.1371/journal.pone.0218471
Clarke, Turner, Angiotensin-converting enzyme 2: the first decade, Int J Hypertens, doi:10.1155/2012/307315
Covid, Team, Covid, Team, Covid et al., Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, Morbidity and mortality weekly report
Flacco, Martellucci, Bravi, Parruti, Cappadona et al., Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis, Heart, doi:10.1136/heartjnl-2020-317336
Gralinski, Menachery, Return of the Coronavirus: 2019-nCoV, Viruses, doi:10.3390/v12020135
Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, doi:10.1001/jamacardio.2020.1017
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with Covid-19
Ivanov, Mihailović-Stanojević, Milanović, Jovović, Marković-Lipkovski et al., Losartan improved antioxidant defense, renal function and structure of postischemic hypertensive kidney, PloS one, doi:10.1371/journal.pone.0096353
Jazzi, Mahnam, Hejazi, Damavandi, Sadeghi et al., Inhibition of viral macrodomain of covid-19 and human trpm2 by losartan, doi:10.20944/preprints202003.0457.v1
Kouhpayeh, Shariati, Boshtam, Rahimmanesh, Mirian et al., The molecular story of COVID-19; NAD+ depletion addresses all questions in this infection, Preprints, doi:10.20944/preprints202003.0346.v1
Liu, Chen, Lin, Han, Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients, J Infection, doi:10.1016/j.jinf.2020.03.005
Mcintyre, Caffe, Michalak, Reid, Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension, Pharmacol Therap, doi:10.1016/S0163-7258(97)82002-5
Meng, Xiao, Zhang, He, Ou et al., Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension, Emerg Microb Infect, doi:10.1080/22221751.2020.1746200
Morse, Lalonde, Xu, Liu, Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV, Chembiochem
Nejat, Sadr, Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study, silico Pharmacol, doi:10.1007/s40203-020-00058-7
Nuzzi, Merlo, Specchia, Lombardi, Carubelli et al., The prognostic value of serial troponin measurements in patients admitted for COVID-19, ESC Heart Failure, doi:10.1002/ehf2.13462
Puskarich, Ingraham, Merck, Driver, Wacker et al., Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial, medRxiv, doi:10.1101/2021.08.25.21262623
Salama, Sadek, Abdelhady, Darweesh, Morsy et al., Losartan may inhibit the progression of liver fibrosis in chronic HCV patients, Hepatob Surg Nutr
Scavone, Brusco, Bertini, Sportiello, Rafaniello et al., Current pharmacological treatments for COVID-19: What's next?, Br J Pharmacol, doi:10.1111/bph.15072
Sellers, Milad, Chan, Mielnik, Jermilova et al., Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function, Am J Pathol, doi:10.1016/j.ajpath.2017.11.006
Shi, Zhang, Jiang, Zhang, Hu et al., Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study, Diabetes care, doi:10.2337/dc20-0598
Tncpere, Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)-China
Wevers, Hoek Lvd, Renin-angiotensin system in human coronavirus pathogenesis, Future Virol, doi:10.2217/fvl.10.4
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, Jama, doi:10.1001/jama.2020.2648
Zeinalian, Salari-Jazi, Jannesari, Khanahmad, A potential protective role of losartan against coronavirus-induced lung damage, Infection Control Hosp Epidemiol, doi:10.1017/ice.2020.80
Zhang, Wang, Jia, Li, Hu et al., Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.04.012
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
{ 'indexed': {'date-parts': [[2023, 9, 1]], 'date-time': '2023-09-01T10:24:29Z', 'timestamp': 1693563869569}, 'reference-count': 29, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T00:00:00Z', 'timestamp': 1647648000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T00:00:00Z', 'timestamp': 1647648000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [{'name': 'Yazd University of Medical Sciences', 'award': ['7867', '7867', '7867', '7867']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 12]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>One of the global problems is to control the coronavirus epidemic, ' 'and the role of different medicines is still unknown to policymakers. This study was ' 'conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in ' 'hypertensive patients.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>The research sample of analytical study included 1458 patients ' 'presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months ' 'of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher’s ' 'exact test, <jats:italic>t</jats:italic> test, and logistic regression.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Of 1458 subjects that were studied, 280 were hypertensive of whom 179 ' 'tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 ' 'times in hypertensive patients who used losartan (<jats:italic>P</jats:italic> = 0.003).\xa0' 'Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive ' 'patients, it was found that this medicine played a protective role although this relationship ' 'was not statistically significant (<jats:italic>P</jats:italic> = 0.86).</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>The results showed that losartan reduced the chance of mortality in ' 'hypertensive patients. It is recommended that the effect of losartan and other blood pressure ' 'medicines on COVID-19 patients be investigated in larger studies as well as laboratory ' 'investigations.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s12872-022-02548-2', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T12:03:22Z', 'timestamp': 1647691402000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 3, 'title': 'Does Losartan reduce the severity of COVID-19 in hypertensive patients?', 'prefix': '10.1186', 'volume': '22', 'author': [ {'given': 'Mohammadreza', 'family': 'Mirjalili', 'sequence': 'first', 'affiliation': []}, {'given': 'Moslem Taheri', 'family': 'Soodejani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehdi', 'family': 'Raadabadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Dehghani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fateme', 'family': 'Salemi', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 3, 19]]}, 'reference': [ { 'issue': '2', 'key': '2548_CR1', 'doi-asserted-by': 'publisher', 'first-page': '135', 'DOI': '10.3390/v12020135', 'volume': '12', 'author': 'LE Gralinski', 'year': '2020', 'unstructured': 'Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. ' 'Viruses. 2020;12(2):135. https://doi.org/10.3390/v12020135.', 'journal-title': 'Viruses'}, { 'issue': '1', 'key': '2548_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.12659/msm.925364', 'volume': '8', 'author': 'MS Alshahrani', 'year': '2018', 'unstructured': 'Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, ' 'et al. Extracorporeal membrane oxygenation for severe Middle East ' 'respiratory syndrome coronavirus. Ann Intensive Care. 2018;8(1):1–10. ' 'https://doi.org/10.12659/msm.925364.', 'journal-title': 'Ann Intensive Care'}, { 'issue': '10229', 'key': '2548_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'volume': '395', 'author': 'F Zhou', 'year': '2020', 'unstructured': 'Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk ' 'factors for mortality of adult inpatients with COVID-19 in Wuhan, China: ' 'a retrospective cohort study. Lancet. 2020;395(10229):1054–62. ' 'https://doi.org/10.1016/S0140-6736(20)30566-3.', 'journal-title': 'Lancet'}, { 'issue': '7', 'key': '2548_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1382', 'DOI': '10.2337/dc20-0598', 'volume': '43', 'author': 'Q Shi', 'year': '2020', 'unstructured': 'Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical ' 'characteristics and risk factors for mortality of COVID-19 patients with ' 'diabetes in Wuhan, China: a two-center, retrospective study. Diabetes ' 'care. 2020;43(7):1382–91. https://doi.org/10.2337/dc20-0598.', 'journal-title': 'Diabetes care'}, { 'issue': '6', 'key': '2548_CR5', 'doi-asserted-by': 'publisher', 'first-page': 'e14-e8', 'DOI': '10.1016/j.jinf.2020.03.005', 'volume': '80', 'author': 'K Liu', 'year': '2020', 'unstructured': 'Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly ' 'patients: a comparison with young and middle-aged patients. J Infection. ' '2020;80(6):e14–8. https://doi.org/10.1016/j.jinf.2020.03.005.', 'journal-title': 'J Infection'}, { 'issue': '13', 'key': '2548_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'volume': '323', 'author': 'Z Wu', 'year': '2020', 'unstructured': 'Wu Z, McGoogan JM. Characteristics of and important lessons from the ' 'coronavirus disease 2019 (COVID-19) outbreak in China: summary of a ' 'report of 72 314 cases from the Chinese Center for Disease Control and ' 'Prevention. Jama. 2020;323(13):1239–42. ' 'https://doi.org/10.1001/jama.2020.2648.', 'journal-title': 'Jama'}, { 'key': '2548_CR7', 'doi-asserted-by': 'publisher', 'unstructured': 'Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, et ' 'al. Effect of losartan on hospitalized patients with COVID-19-induced ' 'lung injury: A randomized clinical trial. medRxiv. 2021. ' 'https://doi.org/10.1101/2021.08.25.21262623.', 'DOI': '10.1101/2021.08.25.21262623'}, { 'issue': '1', 'key': '2548_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1007/s40203-020-00058-7', 'volume': '9', 'author': 'R Nejat', 'year': '2021', 'unstructured': 'Nejat R, Sadr AS. Are losartan and imatinib effective against SARS-CoV2 ' 'pathogenesis? A pathophysiologic-based in silico study. In silico ' 'Pharmacol. 2021;9(1):1–22. https://doi.org/10.1007/s40203-020-00058-7.', 'journal-title': 'In silico Pharmacol'}, { 'key': '2548_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/s13063-017-2427-0', 'volume': '19', 'author': 'YM Arabi', 'year': '2018', 'unstructured': 'Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et ' 'al. Treatment of Middle East respiratory syndrome with a combination of ' 'lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol ' 'for a randomized controlled trial. Trials. 2018;19:1–13. ' 'https://doi.org/10.1186/s13063-017-2427-0.', 'journal-title': 'Trials.'}, { 'key': '2548_CR10', 'doi-asserted-by': 'crossref', 'unstructured': 'Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L. ' 'Dexamethasone in Hospitalized Patients with Covid-19. ' '2021;384(8):693–704. https://dx.doi.org/10.1056%2FNEJMoa2021436.', 'DOI': '10.1056/NEJMoa2021436'}, { 'issue': '21', 'key': '2548_CR11', 'doi-asserted-by': 'publisher', 'first-page': '4813', 'DOI': '10.1111/bph.15072', 'volume': '177', 'author': 'C Scavone', 'year': '2020', 'unstructured': 'Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, ' 'et al. Current pharmacological treatments for COVID-19: What’s next? Br ' 'J Pharmacol. 2020;177(21):4813–24. https://doi.org/10.1111/bph.15072.', 'journal-title': 'Br J Pharmacol'}, { 'key': '2548_CR12', 'doi-asserted-by': 'publisher', 'DOI': '10.20944/preprints202003.0457.v1', 'author': 'AS Jazzi', 'year': '2020', 'unstructured': 'Jazzi AS, Mahnam K, Hejazi SH, Damavandi MS, Sadeghi P, Zeinalian M, et ' 'al. Inhibition of viral macrodomain of covid-19 and human trpm2 by ' 'losartan. Preprint. 2020. ' 'https://doi.org/10.20944/preprints202003.0457.v1.', 'journal-title': 'Preprint'}, { 'issue': '6', 'key': '2548_CR13', 'doi-asserted-by': 'publisher', 'first-page': '752', 'DOI': '10.1017/ice.2020.80', 'volume': '41', 'author': 'M Zeinalian', 'year': '2020', 'unstructured': 'Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. A potential ' 'protective role of losartan against coronavirus-induced lung damage. ' 'Infection Control Hosp Epidemiol. 2020;41(6):752–3. ' 'https://doi.org/10.1017/ice.2020.80.', 'journal-title': 'Infection Control Hosp Epidemiol'}, { 'issue': '19', 'key': '2548_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1519', 'DOI': '10.1136/heartjnl-2020-317336', 'volume': '106', 'author': 'ME Flacco', 'year': '2020', 'unstructured': 'Flacco ME, Martellucci CA, Bravi F, Parruti G, Cappadona R, Mascitelli ' 'A, et al. Treatment with ACE inhibitors or ARBs and risk of ' 'severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519–24. ' 'https://doi.org/10.1136/heartjnl-2020-317336.', 'journal-title': 'Heart'}, { 'issue': '2', 'key': '2548_CR15', 'doi-asserted-by': 'publisher', 'first-page': '145', 'DOI': '10.2217/fvl.10.4', 'volume': '5', 'author': 'BA Wevers', 'year': '2010', 'unstructured': 'Wevers BA. Hoek Lvd. Renin–angiotensin system in human coronavirus ' 'pathogenesis. Future Virol. 2010;5(2):145–61. ' 'https://doi.org/10.2217/fvl.10.4.', 'journal-title': 'Future Virol'}, { 'key': '2548_CR16', 'doi-asserted-by': 'publisher', 'unstructured': 'Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. ' 'Int J Hypertens. 2012;2012. https://doi.org/10.1155/2012/307315.', 'DOI': '10.1155/2012/307315'}, { 'issue': '2', 'key': '2548_CR17', 'doi-asserted-by': 'publisher', 'first-page': '181', 'DOI': '10.1016/S0163-7258(97)82002-5', 'volume': '74', 'author': 'M McIntyre', 'year': '1997', 'unstructured': 'McIntyre M, Caffe S, Michalak R, Reid J. Losartan, an orally active ' 'angiotensin (AT1) receptor antagonist: a review of its efficacy and ' 'safety in essential hypertension. Pharmacol Therap. 1997;74(2):181–94. ' 'https://doi.org/10.1016/S0163-7258(97)82002-5.', 'journal-title': 'Pharmacol Therap'}, { 'issue': '3', 'key': '2548_CR18', 'doi-asserted-by': 'publisher', 'first-page': '249', 'DOI': '10.21037/hbsn.2016.02.06', 'volume': '5', 'author': 'ZA Salama', 'year': '2016', 'unstructured': 'Salama ZA, Sadek A, Abdelhady AM, Darweesh SK, Morsy SA, Esmat G. ' 'Losartan may inhibit the progression of liver fibrosis in chronic HCV ' 'patients. Hepatob Surg Nutr. 2016;5(3):249.', 'journal-title': 'Hepatob Surg Nutr'}, { 'issue': '3', 'key': '2548_CR19', 'doi-asserted-by': 'publisher', 'first-page': '574', 'DOI': '10.1016/j.ajpath.2017.11.006', 'volume': '188', 'author': 'SL Sellers', 'year': '2018', 'unstructured': 'Sellers SL, Milad N, Chan R, Mielnik M, Jermilova U, Huang PL, et al. ' 'Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of ' 'Angiotensin II Receptor Type 1–Independent Activation of Endothelial ' 'Function. Am J Pathol. 2018;188(3):574–85. ' 'https://doi.org/10.1016/j.ajpath.2017.11.006.', 'journal-title': 'Am J Pathol'}, { 'issue': '6', 'key': '2548_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'e0218471', 'DOI': '10.1371/journal.pone.0218471', 'volume': '14', 'author': 'JA Choi', 'year': '2019', 'unstructured': 'Choi JA, Kim J-E, Ju H-h, Lee J, Jee D, Park CK, et al. The effects of ' 'losartan on cytomegalovirus infection in human trabecular meshwork ' 'cells. Plos one. 2019;14(6):e0218471. ' 'https://doi.org/10.1371/journal.pone.0218471.', 'journal-title': 'Plos one'}, { 'issue': '5', 'key': '2548_CR21', 'doi-asserted-by': 'publisher', 'first-page': '730', 'DOI': '10.1002/cbic.202000047', 'volume': '21', 'author': 'JS Morse', 'year': '2020', 'unstructured': 'Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible ' 'urgent prevention and treatment options for severe acute respiratory ' 'infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730. ' 'https://dx.doi.org/10.1002%2Fcbic.202000047.', 'journal-title': 'Chembiochem'}, { 'issue': '5', 'key': '2548_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e96353', 'DOI': '10.1371/journal.pone.0096353', 'volume': '9', 'author': 'M Ivanov', 'year': '2014', 'unstructured': 'Ivanov M, Mihailović-Stanojević N, Grujić Milanović J, Jovović Đ, ' 'Marković-Lipkovski J, Ćirović S, et al. Losartan improved antioxidant ' 'defense, renal function and structure of postischemic hypertensive ' 'kidney. PloS one. 2014;9(5):e96353. ' 'https://doi.org/10.1371/journal.pone.0096353.', 'journal-title': 'PloS one'}, { 'key': '2548_CR23', 'doi-asserted-by': 'publisher', 'unstructured': 'Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Zeinalian ' 'M, et al. The molecular story of COVID-19; NAD+ depletion addresses all ' 'questions in this infection. 2020. Kouhpayeh, S.; Shariati, L.; Boshtam, ' 'M.; Rahimmanesh, I.; Mirian, M.; Zeinalian, M.; Salari-jazi, A.; ' 'Khanahmad, N.; Damavandi, M.S.; Sadeghi, P.; Khanahmad, H. The Molecular ' 'Story of COVID-19; NAD+ Depletion Addresses All Questions in this ' 'Infection. Preprints 2020, 2020030346 ' 'https://doi.org/10.20944/preprints202003.0346.v1.', 'DOI': '10.20944/preprints202003.0346.v1'}, { 'key': '2548_CR24', 'doi-asserted-by': 'crossref', 'unstructured': 'Covid C, Team R, COVID C, Team R, COVID C, Team R, et al. Severe ' 'outcomes among patients with coronavirus disease 2019 (COVID-19)—United ' 'States, February 12–March 16, 2020. Morbidity and mortality weekly ' 'report. 2020;69(12):343. https://dx.doi.org/10.15585%2Fmmwr.mm6912e2.', 'DOI': '10.15585/mmwr.mm6912e2'}, { 'key': '2548_CR25', 'unstructured': 'TNCPERE T. Vital surveillances: the epidemiological characteristics of ' 'an outbreak of 2019 novel coronavirus disease (COVID-19)-China, 2020. ' '2020.'}, { 'issue': '6', 'key': '2548_CR26', 'doi-asserted-by': 'publisher', 'first-page': '767', 'DOI': '10.1016/j.cmi.2020.04.012', 'volume': '26', 'author': 'J Zhang', 'year': '2020', 'unstructured': 'Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for ' 'disease severity, unimprovement, and mortality in COVID-19 patients in ' 'Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72. ' 'https://doi.org/10.1016/j.cmi.2020.04.012.', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '7', 'key': '2548_CR27', 'doi-asserted-by': 'publisher', 'first-page': '811', 'DOI': '10.1001/jamacardio.2020.1017', 'volume': '5', 'author': 'T Guo', 'year': '2020', 'unstructured': 'Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular ' 'implications of fatal outcomes of patients with coronavirus disease 2019 ' '(COVID-19). JAMA Cardiol. 2020;5(7):811–8. ' 'https://doi.org/10.1001/jamacardio.2020.1017.', 'journal-title': 'JAMA Cardiol'}, { 'issue': '5', 'key': '2548_CR28', 'doi-asserted-by': 'publisher', 'first-page': '3504', 'DOI': '10.1002/ehf2.13462', 'volume': '8', 'author': 'V Nuzzi', 'year': '2021', 'unstructured': 'Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, et al. ' 'The prognostic value of serial troponin measurements in patients ' 'admitted for COVID-19. ESC Heart Failure. 2021;8(5):3504–11. ' 'https://doi.org/10.1002/ehf2.13462.', 'journal-title': 'ESC Heart Failure'}, { 'issue': '1', 'key': '2548_CR29', 'doi-asserted-by': 'publisher', 'first-page': '757', 'DOI': '10.1080/22221751.2020.1746200', 'volume': '9', 'author': 'J Meng', 'year': '2020', 'unstructured': 'Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin ' 'system inhibitors improve the clinical outcomes of COVID-19 patients ' 'with hypertension. Emerg Microb Infect. 2020;9(1):757–60. ' 'https://doi.org/10.1080/22221751.2020.1746200.', 'journal-title': 'Emerg Microb Infect'}], 'container-title': 'BMC Cardiovascular Disorders', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12872-022-02548-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12872-022-02548-2/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12872-022-02548-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T12:09:27Z', 'timestamp': 1647691767000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-022-02548-2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 19]]}, 'references-count': 29, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['2548'], 'URL': 'http://dx.doi.org/10.1186/s12872-022-02548-2', 'relation': {}, 'ISSN': ['1471-2261'], 'subject': [], 'container-title-short': 'BMC Cardiovasc Disord', 'published': {'date-parts': [[2022, 3, 19]]}, 'assertion': [ { 'value': '22 August 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '8 March 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 March 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The article’s proposal was approved by the ethics committee of Shahid Sadoughi ' 'University of Medical Sciences with the ID of IR.SSU.REC.1399.101. Due to the ' 'retrospective nature of the study, no study specific consent form was used. ' 'However, patients admitted to our hospital are asked to sign a general consent ' 'upon admission, which covers the collection of patient data and publication of ' 'these results. Therefore, the individual’s informed consent was waived by the ' 'above ethics committee. We received administrative permission from (Secretary ' 'of University/Regional Research Ethics Committee Shahid Sadoughi University of ' 'Medical Sciences) to access and use the data. Data used in the study were ' 'anonymized. The ethics committee approved this procedure with the above ' 'ethical code. The present study was conducted in terms of the principles of ' 'the revised Declaration of Helsinki, which waived requirement for informed ' 'consent.', 'order': 2, 'name': 'Ethics', 'group': { 'name': 'EthicsHeading', 'label': "<!--Emphasis Type='Bold' removed-->Ethics approval and consent to " 'participate'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': { 'name': 'EthicsHeading', 'label': "<!--Emphasis Type='Bold' removed-->Consent for publication"}}, { 'value': 'All authors declare that they have no conflict of interest regarding this ' 'study.', 'order': 4, 'name': 'Ethics', 'group': { 'name': 'EthicsHeading', 'label': "<!--Emphasis Type='Bold' removed-->Competing interests"}}], 'article-number': '116'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit